Bioventus falls 16.7% after quarterly results weigh on surgical products

What happened

Bioventus (BVS) fell 16.7% on November 3, 2026, because of its third-quarter results, with trading volume 5.7 times its 20-day average. The stock opened 16.2% below the previous close and closed at $10.95 as investors digested the company’s update on revenue and segment performance. The S&P 500 rose 0.4% on the day while the healthcare sector median rose 0.6%, making the stock’s decline 17.4 percentage points worse than the sector median.

How big was the move

The session was 4.7 times a typical daily move for this stock, a sharp reaction given Bioventus’s beta of 0.75, which means the stock tends to move less than the market. Trading volume was 5.7 times its 20-day average. Over the last five sessions the stock fell 24.1% while the S&P 500 fell 2.0% in the same period, underscoring that the move was driven by company-specific news rather than broad market weakness.

The technical picture

The stock sits 20.1% below its 20-day moving average and 19.6% below its 50-day moving average, though it is 0.1% above its 200-day moving average. The 50-day average is above the 200-day average, a sign of an established uptrend, and the stock has spent 108 consecutive trading days above the 200-day average. The Relative Strength Index (14 days) is 29, below 30, a level often called oversold. The shares are 31.1% below the 52-week high. Over one month the stock fell 19.0% and over three months it fell 28.2%, but over one year it rose 67.2%, which is 56.5 percentage points ahead of the S&P 500.

Fundamentals and valuation

For the four quarters through September 26, 2026, revenue was $585.6 million, which grew 3.9% from a year earlier. Diluted earnings per share for that period were $0.80, and earnings per share growth rose 606.9% from a year earlier. Gross margin was 68.3% compared with 67.0% a year earlier, and operating margin was 10.1% versus 7.7% a year earlier, reflecting improved profitability on the reported basis.

Free-cash-flow margin stood at 14.5% and return on invested capital was 11.4%, while the balance sheet shows net debt of 2.1 times EBITDA. Share count over one year increased by 5.3%. On valuation metrics, the stock carries a Price to trailing earnings of 13.6 times trailing earnings and a Price to forward earnings of 14.1 times expected earnings, with a free-cash-flow yield of 9.3%.

PromtFinance scores place the company highly on Value at 98 (Exceptional), with positive marks for Growth at 71 and Quality at 75, and strong Revisions at 82. Those scores suggest investors looking for value may view the recent selloff as an entry, while the rise in share count and leverage metrics will be factors for investors focused on capital structure and dilution.

Earnings and analyst expectations

Bioventus reported on November 2, 2026, posting quarterly earnings per share of $0.17 against $0.15 expected, 13.6% above estimates, marking four consecutive quarters beating estimates. The average surprise over the last four reports was 22.8% above estimates. Typical two-day reactions after recent reports were to rise 8.4%, but the market responded differently this session as specifics about segment weakness became prominent. The next report is scheduled for March 4, 2027.

The company’s disclosure said revenue growth was driven by strength in its Pain Treatments business, Ultrasonics operations, and international markets, while softness in bone graft substitutes within Surgical Solutions weighed on results. That segment weakness, despite overall revenue growth, appears to have prompted the heavier-than-typical selling and the re-pricing of the shares on November 3.

What to watch

• March 4, 2027: next scheduled earnings report
• Consensus price target $18.33, 67.4% above the closing price
• Four consecutive quarters beating estimates, average surprise 22.8% above estimates
• Net debt of 2.1 times EBITDA and free-cash-flow margin of 14.5%
• Share count increased by 5.3% over one year